Difference between revisions of "Temozolomide (Temodar)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
m (updated diseases)
Line 1: Line 1:
 +
Also known as Temcad and Temodal.
 +
 
==General information==
 
==General information==
Class/mechanism: Alkylator.  Temozolmide is converted in vivo to the reactive compound 5-(3-methyltriazen-
+
Class/mechanism: Alkylator.  Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen-
1-yl)-imidazole-4-carboxamide (MTIC).  MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.<ref name="insert">[http://www.spfiles.com/pitemodar.pdf Temozolomide (Temodar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/temozolomide.pdf Temozolomide (Temodar) package insert (locally hosted backup)]</ref><ref>[http://temodar.com Temodar manufacturer's website]</ref>
+
1-yl)-imidazole-4-carboxamide (MTIC).  MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.<ref name="insert">[http://www.spfiles.com/pitemodar.pdf Temozolomide (Temodar) package insert]</ref><ref>[[Media:Temozolomide.pdf | Temozolomide (Temodar) package insert (locally hosted backup)]]</ref><ref>[http://temodar.com Temodar manufacturer's website]</ref>
 
<br>Route: PO, IV
 
<br>Route: PO, IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is used==
 +
*[[Bone cancer]]
 +
*[[Central nervous system (CNS) cancer]]
 +
*[[Melanoma]]
  
 
==Patient drug information==
 
==Patient drug information==

Revision as of 04:18, 4 September 2012

Also known as Temcad and Temodal.

General information

Class/mechanism: Alkylator. Temozolomide is converted in vivo to the reactive compound 5-(3-methyltriazen- 1-yl)-imidazole-4-carboxamide (MTIC). MTIC causes alkylation of DNA at the O6 and N7 positions of guanine, leading to cell damage and cell death.[1][2][3]
Route: PO, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

References